FY2028 EPS Estimates for PolyPid Boosted by HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Investment analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of PolyPid in a research note issued on Wednesday, February 11th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.21 per share for the year, up from their previous estimate of $0.20. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $4.02 EPS.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th. Citigroup restated a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. Finally, Roth Mkm cut their price objective on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Trading Down 3.5%

Shares of NASDAQ PYPD opened at $4.43 on Thursday. PolyPid has a 12-month low of $2.30 and a 12-month high of $5.12. The stock’s fifty day simple moving average is $4.37 and its two-hundred day simple moving average is $3.81. The stock has a market capitalization of $70.44 million, a PE ratio of -1.96 and a beta of 1.52.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.07).

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PYPD. AIGH Capital Management LLC raised its holdings in shares of PolyPid by 27.0% in the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after buying an additional 253,727 shares during the last quarter. Lumbard & Kellner LLC acquired a new position in shares of PolyPid in the 2nd quarter valued at $135,000. BNP Paribas Financial Markets raised its stake in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares during the last quarter. HighTower Advisors LLC acquired a new stake in PolyPid during the 4th quarter worth about $44,000. Finally, Jane Street Group LLC acquired a new stake in PolyPid during the 4th quarter worth about $66,000. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid News Summary

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $13 price target and models significant long‑term upside (FY2028 and FY2030 estimates were raised to positive territory), which supports a bullish narrative for PYPD’s eventual commercial prospects.
• Positive Sentiment: Management’s Q4 earnings call was described as upbeat and flagged a potentially material 2026 catalyst that investors may view as a near‑term growth trigger. PolyPid Earnings Call Flags Big 2026 Catalyst
• Neutral Sentiment: Full Q4 2025 earnings call transcript and highlight coverage are available for investors who want details on pipeline timing, trial milestones and cash guidance; these provide context but may not move the stock until the 2026 catalyst is clarified. Q4 2025 Earnings Call Highlights Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright materially lowered FY2026 EPS estimates (now forecasting a larger loss: -$1.69 vs prior -$1.46) and trimmed FY2029 slightly, signaling worse near‑term profitability than previously expected — a negative for short‑term sentiment.
• Negative Sentiment: PolyPid missed Q4 EPS expectations (reported -$0.41 vs consensus -$0.34), underscoring current cash‑burn/loss trends that weigh on the share price until clinical or commercial catalysts materialize. Earnings Call Transcript

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.